Semi-Glycigon Tablet

Semi-Glycigon Tablet contains Gliclazide, belongs to the sulfonylurea class, and is utilized in the treatment of type 2 diabetes. It is a beneficial option when lifestyle modifications, exercise, and weight loss efforts fall short in managing blood sugar levels.

Gliclazide operates primarily by selectively binding to sulfonylurea receptors on the pancreatic beta cells, leading to the closure of potassium ion channels. This action triggers depolarization of the cell, opening calcium ion channels, increasing calcium influx, and eventually resulting in the release of insulin vesicles, thereby promoting insulin secretion.

The prescribed dosage and administration guidelines may vary, and it is essential to adhere to the recommendations provided by healthcare professionals.

While Gliclazide can be beneficial, it may be accompanied by certain side effects. Common side effects include hypoglycemia. Less frequent effects encompass hypertension, dizziness, hyperglycemia, viral infection, and back pain. Rare side effects involve cystitis, weight gain, and vomiting.

Gliclazide is contraindicated in individuals with type 1 diabetes, hypersensitivity to sulfonylureas, severe renal or hepatic failure, and during pregnancy or lactation. It is advised to monitor blood sugar levels regularly during treatment, especially in stressful conditions.

In the event of a missed dose, it is recommended to take it as soon as possible. However, if the next scheduled dose is approaching, it is advisable to skip the missed one to prevent a potential double dosage.